Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
Chee Wah Tan, Wan Ni Chia, Xijian Qin, et al.
Nature Biotechnology (2020) Vol. 38, Iss. 9, pp. 1073-1078
Open Access | Times Cited: 1252

Showing 1-25 of 1252 citing articles:

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Nina Le Bert, Anthony T. Tan, Kamini Kunasegaran, et al.
Nature (2020) Vol. 584, Iss. 7821, pp. 457-462
Open Access | Times Cited: 2051
Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli, Young‐Jun Park, M. Alejandra Tortorici, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 1024-1042.e21
Open Access | Times Cited: 1438
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
Anthony T. Tan, Martin Linster, Chee Wah Tan, et al.
Cell Reports (2021) Vol. 34, Iss. 6, pp. 108728-108728
Open Access | Times Cited: 692
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Lauren B. Rodda, Jason Netland, Laila Shehata, et al.
Cell (2020) Vol. 184, Iss. 1, pp. 169-183.e17
Open Access | Times Cited: 669
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
Paul Naaber, Liina Tserel, Kadri Kangro, et al.
The Lancet Regional Health - Europe (2021) Vol. 10, pp. 100208-100208
Open Access | Times Cited: 633
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
Wan Ni Chia, Feng Zhu, Sean Wei Xiang Ong, et al.
The Lancet Microbe (2021) Vol. 2, Iss. 6, pp. e240-e249
Open Access | Times Cited: 380
Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia
Supaporn Wacharapluesadee, Chee Wah Tan, Patarapol Maneeorn, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 377
Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity
Tyler J. Ripperger, Jennifer L. Uhrlaub, Makiko Watanabe, et al.
Immunity (2020) Vol. 53, Iss. 5, pp. 925-933.e4
Open Access | Times Cited: 341
Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection
Seyed Hamid Safiabadi Tali, Jason J. LeBlanc, Zubi Sadiq, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 3
Open Access | Times Cited: 335
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
Nina Le Bert, Hannah Clapham, Anthony T. Tan, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 5
Open Access | Times Cited: 321
Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic
Kelvin Kai‐Wang To, Siddharth Sridhar, Kelvin Hei‐Yeung Chiu, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 507-535
Open Access | Times Cited: 297
Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study
Po Ying Chia, Sean Wei Xiang Ong, Calvin J. Chiew, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 4, pp. 612.e1-612.e7
Open Access | Times Cited: 295
Coronavirus disease 2019 (COVID‐19): An overview of the immunopathology, serological diagnosis and management
Abubakar Umar Anka, Mohammed Ibrahim Tahir, Sharafudeen Dahiru Abubakar, et al.
Scandinavian Journal of Immunology (2020) Vol. 93, Iss. 4
Open Access | Times Cited: 293
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Sam Afkhami, Michael R. D’Agostino, Ali Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 896-915.e19
Open Access | Times Cited: 264
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Nicholas A. Kennedy, Simeng Lin, James Goodhand, et al.
Gut (2021) Vol. 70, Iss. 10, pp. 1884-1893
Open Access | Times Cited: 263
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Marc Lipsitch, Yonatan H. Grad, Alessandro Sette, et al.
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 709-713
Open Access | Times Cited: 262
SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )
Jeffrey C. Chandler, Sarah N. Bevins, Jeremy W. Ellis, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 47
Open Access | Times Cited: 255
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Tiong Kit Tan, Pramila Rijal, Rolle Rahikainen, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 248
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Yannick Galipeau, Matthew Greig, George Liu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 242
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Ioannis P. Trougakos, Κimon Stamatelopoulos, Evangelos Terpos, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 240
A simple protein-based surrogate neutralization assay for SARS-CoV-2
Kento T. Abe, Zhijie Li, Reuben Samson, et al.
JCI Insight (2020) Vol. 5, Iss. 19
Open Access | Times Cited: 224
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study
Oon Tek Ng, Kalisvar Marimuthu, Vanessa Koh, et al.
The Lancet Infectious Diseases (2020) Vol. 21, Iss. 3, pp. 333-343
Open Access | Times Cited: 221
A human coronavirus evolves antigenically to escape antibody immunity
Rachel Eguia, Katharine H. D. Crawford, Terry Stevens-Ayers, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 4, pp. e1009453-e1009453
Open Access | Times Cited: 221
Page 1 - Next Page

Scroll to top